Diego Villa, MD, MPH, discusses the findings of a retrospective analysis looking at bendamustine plus rituximab in mantle cell lymphoma.
Diego Villa, MD, MPH, clinical associate professor, Division of Medical Oncology, Department of Medicine, The University of British Columbia, discusses the findings of a retrospective analysis looking at bendamustine plus rituximab (Rituxan; BR) in mantle cell lymphoma (MCL).
The retrospective analysis reflects the The University of British Columbia’s experience with treating patients with BR over the past 6 years, Villa explains. In 2013, the institution made a decision to treat all patients with MCL with upfront BR regardless of transplant-eligibility status, says Villa.
The analysis showed an overall response rate of 87% and a complete response rate of 54%. There was no difference in response rates between patients over the age of 65 years or under the age of 65 years, concludes Villa.